News

October 9, 2017October 9, 2017

After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients

News

Mateon Therapeutics announced that it is immediately ending the FOCUS trial of CA4P to treat platinum-resistant ovarian cancer, based on disappointing interim results. The results showed that CA4P (fosbretabulin) did not significantly ... Read more

October 6, 2017October 6, 2017

TESARO Partners with Olympian Shannon Miller to Expand Program for Ovarian Cancer Community

News

TESARO, a biopharmaceutical company working on new cancer therapies, has launched a number of new resources and services for women living with ovarian cancer, as part of the expansion of its ... Read more

October 4, 2017

Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients

News

All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion‘s GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who ... Read more

October 2, 2017

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

News

Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 ... Read more

September 29, 2017September 29, 2017

Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer

News

Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European Society ... Read more

September 27, 2017September 27, 2017

Chemotherapy Every 3 Weeks Seen as Effective as Weekly Dosing in European Ovarian Cancer Patients

News

Researchers compared weekly doses of Taxol (paclitaxel) to treat ovarian cancer with dosing every three weeks in a European trial to determine if weekly dosing was more effective. They found that ... Read more

September 25, 2017September 25, 2017

Canadian Review Panel Recommends Lynparza Reimbursement

News

AstraZeneca Canada recently announced that Lynparza (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer, recently received a positive clinical recommendation for reimbursement by the pan-Canadian Oncology Drug Review (pCODR) panel. This ... Read more

September 22, 2017September 22, 2017

DelMar Announces VAL-083 Clinical Trials Will Soon Start for Recurrent Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved DelMar Pharmaceuticals’ investigational new drug (IND) application for VAL-083 for the treatment of ovarian cancer. The IND approval allows the company ... Read more

September 20, 2017

CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows

News

Data from the second interim analysis of the ongoing Phase 2/3 FOCUS study has shown that Mateon Therapeutics’ CA4P (combretastatin a4-phosphate), also known as fosbretabulin, may prolong the time to disease ... Read more

September 18, 2017

Tesaro’s Ovarian Cancer Therapy Zejula Moves One Step Closer to EU Approval

News

The European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tesaro‘s Zejula (niraparib) as a maintenance therapy for recurrent platinum-sensitive ovarian ... Read more